Core Viewpoint - Spectral AI, Inc. has announced a $7.6 million offering to support the growth and development of its DeepView System, aimed at enhancing medical diagnostics in wound care [1][3]. Financing Details - The offering consists of 4,000,000 shares of common stock and pre-funded warrants priced at $1.90 per share, with corresponding warrants having an exercise price of $2.51 per share [2]. Company Strategy and Development - The Chairman of the Board expressed satisfaction in securing institutional funding, which will facilitate the continued development of the DeepView System and prepare it for commercial readiness in 2026 [3]. - The company remains committed to its BARDA Project BioShield contract while advancing its AI technology to expand product offerings [3]. About the DeepView System - The DeepView System is designed to provide clinicians with an objective assessment of a burn wound's healing potential, aiming to improve patient outcomes and reduce healthcare costs [5]. - The system utilizes algorithm-driven results to exceed current standards of care in wound management [5].

WEST DES MOINES, Iowa, Oct. 23, 2025 (GLOBE NEWSWIRE) -- West Bancorporation, Inc. (Nasdaq: WTBA; the “Company”), parent company of West Bank, today reported third quarter 2025 net income of $9.3 million, or $0.55 per diluted common share, compared to second quarter 2025 net income of $8.0 million, or $0.47 per diluted common share, and third quarter 2024 net income of $6.0 million, or $0.35 per diluted common share. For the first nine months of 2025, net income was $25.1 million, or $1.48 per diluted commo ...

BERKELEY HEIGHTS, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that DefenCath has received an Innovative Technology designation from Vizient®, the largest healthcare performance improvement company in the country. CorMedix exhibited DefenCath at the Vizient Innovative Technology Exchange September 17th in Las Vegas, Nevada. Each yea ...

NEW YORK, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Carlyle Credit Income Fund (the “Fund”) (NYSE: CCIF) today announced that it has commenced an underwritten public offering of its Series D Preferred Shares (the “Preferred Shares”). The public offering price and other terms of the Preferred Shares are to be determined by negotiations between the Fund and the underwriters. The Preferred Shares are rated ‘BBB+’ by Egan-Jones Ratings Company, an independent rating agency. In addition, the Fund plans to grant the unde ...

Neve Yarak, Israel, Oct. 23, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a cleantech company investing in solar energy assets based on the RTB (Ready to Build) business model, announced today the closing of the merger with MitoCareX Bio Ltd. ("MitoCareX"), a biotech company focused on drug discovery targeting cancer therapeutics, with a range of other potential diseases and disorders, through targeting the mitochondrial SLC25 protein family. MitoCareX is focusing on the ...

Core Viewpoint - Quantum BioPharma Ltd. announces a $5 million Reg D 506(c) offering through its licensee Unbuzzd Wellness Inc., which has developed a beverage that accelerates alcohol metabolism and reduces hangover symptoms, with no dilution for Quantum BioPharma shareholders [1][4]. Company Overview - Quantum BioPharma is focused on innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, with drug candidates at various development stages [1][8]. - The company retains a 20.10% ownership stake in Unbuzzd Wellness Inc. and is entitled to a 7% royalty on sales until reaching $250 million, after which the royalty will decrease to 3% [8]. Unbuzzd Wellness Inc. Details - Unbuzzd Wellness Inc. is a public issuer specializing in wellness and recovery supplements, with a product designed to enhance alcohol metabolism and cognitive function [5][8]. - The beverage, unbuzzd, is backed by clinical research and aims to meet consumer needs for responsible drinking [3][5]. Clinical Trial Findings - A clinical trial demonstrated that unbuzzd accelerates alcohol metabolism, reducing blood alcohol concentration (BAC) by over 40% faster within 30 minutes compared to control subjects [6][12]. - Participants reported significant improvements in alertness and cognitive performance shortly after consuming unbuzzd, with no adverse side effects noted [6][12]. Investor Webinar - An investor webinar is scheduled for October 30, 2025, where Unbuzzd leadership will discuss the investment opportunity and plans for scaling distribution [2][3]. - The offering is targeted at accredited investors, aiming to expand direct-to-consumer and retail availability, with potential plans for an IPO [3].

Core Insights - ZenaTech has established Zena AI, Inc. in Baton Rouge, Louisiana, focusing on developing next-generation drone technologies for US defense and homeland security applications [1][2] - The company plans to hire up to eight AI software and engineering specialists by the end of the year to support its R&D efforts [1][2] - The initiatives align with the White House's AI Action Plan and recent Executive Orders aimed at promoting domestic AI innovation [4] Company Overview - ZenaTech specializes in AI drones, Drone as a Service (DaaS), enterprise SaaS, and Quantum Computing solutions, serving various sectors including law enforcement, health, government, and industrial applications [5][6] - The company has been expanding its drone design and manufacturing capabilities since 2017, with a focus on improving operational efficiencies and cost savings for its customers [5] - ZenaDrone, a subsidiary of ZenaTech, develops autonomous drone solutions that incorporate advanced technologies such as machine learning and quantum computing [6] Development Focus - The Baton Rouge facility will host a multidisciplinary team working on advanced applications such as autonomous navigation, drone fleet coordination, and real-time decision-making [2][3] - The Eagle Eye project aims to integrate AI drones with historical and real-time data, leveraging quantum computing for predictive insights and optimized battlefield performance [3]

ROCKAWAY, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report financial results for the third quarter ended September 30, 2025, after the close of the market on Wednesday, November 5, 2025. Management will host a webinar at 4:30 PM EST to review the financial results and answer questions. Investors can access the webinar using the details below: Wednesday, November 5, 4:30 PM ESTDial-In: ...

Positioned to Capture Opportunities in the US$71 Billion Crypto-Exchange Market and the US$24 Billion Tokenized Asset Sector, Combining Blockchain Innovation with Tangible ValueKUALA LUMPUR, Malaysia, Oct. 23, 2025 (GLOBE NEWSWIRE) -- VCI Global Limited (NASDAQ: VCIG) (“VCI Global” or the “Company”), today announced that its subsidiary Smart Bridge Technologies Limited (“Smart Bridge”) is preparing to launch an Ethereum-based crypto–fiat platform that integrates digital assets, gold, and traditional finance ...

Company launches multi-channel promotional campaign to drive market adoption U.S. losartan market totals $256M annually with 71M prescriptions, creating a significant opportunity for Arbli™ as the first FDA-approved ready-to-use oral suspension COMMACK, NY, Oct. 23, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, c ...